CDC Guidance Considers Tecovirimat in Monkeypox
The Centers for Disease Control and Prevention (CDC) has provided guidelines on using Siga Technologies’ Tpoxx (tecovirimat) in treating monkeypox.
The CDC said Tpoxx should be considered in people who show severe disease and involvement of anatomic areas that might result in serious sequelae, including scarring or strictures.
The drug should also be considered for use in people who are at high risk for severe disease, the CDC said, including severely immunocompromised individuals. The agency said it should also be considered for pediatric populations, especially children under eight years old, pregnant and breastfeeding women, and people with conditions affecting skin integrity.
Tpoxx isn’t currently FDA-approved for use in patients with monkeypox. The agency says more data from randomized clinical trials are needed to prove the drug’s safety and efficacy for monkeypox.